CCL17 and lung cancer: Meanwhile, CCL17 high expression had a positive effect on the prognosis of lung cancer patients in T1 (OS, HR = 0.63 (0.46–0.86), p = 0.0029; PFS, HR = 0.39 (0.24–0.65),p = 0.0002), N0 (OS, HR = 0.73 (0.53–0.93), p = 0.012; PFS, HR = 0.7 (0.49–0.98),p = 0.0366), N1 (OS, HR = 0.72 (0.5–0.99), p = 0.0445), and M0 (OS, HR = 0.68 (0.54–0.87), p = 0.0015) but was not associated with OS and PFS in T2, T4, and N2 stages and PFS in N1 and M0 stages.